We have developed CD6-knockout mice and CD6-humanized mice and showed the genetic depletion of CD6, or pharmaceutic blockage of CD6 using mAbs, protects the mice from models of T cell–mediated diseases such as multiple sclerosis (11), rheumatoid arthritis (12), and autoimmune uveitis (13). This evidence concerns the gene CD6 and multiple sclerosis.